Pulmonary-delivered Anticalin Jagged-1 antagonists reduce experimental airway mucus hyperproduction and obstruction

2024/11/05 by Katharina Heinzelmann, Athanasios Fysikopoulos, Thomas J. Jaquin +20
Medicine · #Cystic Fibrosis Research Advances #Neonatal Respiratory Health Research #Tracheal and airway disorders

paper · doi:10.1152/ajplung.00059.2024

openalex publication_date 2024/11/05 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/22

Abstract

Airway mucus drives severity and mortality in diverse chronic lung diseases. The Jagged-1/Notch pathway controls the balance of ciliated versus mucous cells, but targeting the pathway systemically carries the risk of side effects. Here we developed novel, Anticalin-derived, pulmonary-delivered Jagged-1 antagonists, to inhibit airway mucus hyperproduction and obstruction in chronic lung diseases. Our preclinical data demonstrate the effectiveness of these antagonists in diminishing secretory cell and mucus levels and alleviating hallmarks of mucus obstruction.

Citations

• Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung
• Physiology and pathophysiology of human airway mucus

Related

• Physiology and pathophysiology of human airway mucus
• Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives
• Ogremorphin inhibits GPR68 mediated MUC5AC expression
• CFTR-independent prostaglandin E 2 -stimulated chloride secretion in human airway
• Relaxation of Contracted Rabbit Tracheal and Human Bronchial Smooth Muscle by Y-27632 through Inhibition of Ca2 + Sensitization